-
Product Insights
TM 2 Mine
The TM 2 Mine is a coal mine in United States. It is currently in operation. Empower your strategies with our TM 2 Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...
-
Product Insights
TM Invest Niksic Solar PV Park
TM Invest Niksic Solar PV Park is a solar PV project located in Niksic, Montenegro. The project is expected to come online in 2026. Empower your strategies with our TM Invest Niksic Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986218 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986218 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986218 in Melanoma Drug Details: BMS-986218 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Q-Cells in Transverse Myelitis (TM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Q-Cells in Transverse Myelitis (TM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Q-Cells in Transverse Myelitis (TM) Drug Details: Q-Cells is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TMS-007 in Acute Ischemic Stroke
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TMS-007 in Acute Ischemic StrokeDrug Details:TMS-007 (Stachybotrys microspora triprenyl phenol-7) is under development for the treatment...
-
Product Insights
Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2023’, provides an overview of the Cancer Anorexia-Cachexia Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs In Development, 2023’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuropathy - Drugs In Development, 2023’, provides an overview of the Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...